Two and a half years.
Very long.
The launch of the Transcription Fluid, its clinical trial almost didn't take half of that time, even shorter. The nurse knew this, the main reason was not immature technology.
It was caution.
After all.
If it's cancer.
The mortality rate is high, and most survival times are short, but Alzheimer's disease is different; it's a chronic developing disease. Hence, the former is more urgent.
The latter is not so urgent.
Therefore.
Considering comprehensively, time was extended. Over two years of treatment, over two years of observation, confirming no aftermath and other impacts afterward.
That's the only time it was launched.
Otherwise.
It might make people think it's too unprofessional, crazily obsessed with money, but even so, it's still shorter compared to those international drugs' clinical trials, which averaged ten years.
Ten years.
Oh!
Probably a large group of people would leave.
Two and a half years.
No more.
No less.
